MV

Mark Velleca

Biotech Executive

Washington, District of Columbia

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Education

Lists including Mark

AP
AO
AS
AN

Based in UK

1884 people

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Work Experience

BD
Black Diamond Therapeutics

2021

  • CEO

    2023

  • Board Chair

    2022

  • Board Director

    2021 - 2022

i
iOnctura

2024

  • Board Chair

    2024

MT
Myeloid Therapeutics

2023

  • Board Chair

    2023

GT
G1 Therapeutics, Inc.

2021 - 2024

  • Board Director, Senior Advisor

    2021 - 2024

    Pharmacosmos acquired G1 in 2024

HV
Hatteras Venture Partners

2021 - 2023

  • Venture Partner

    2021 - 2023

SI
StrideBio, Inc

2021 - 2023

  • Advisor, CEO, Board Director

    2021 - 2023

    Ginkgo acquired StrideBio's assets in 2023

IT
IMMvention Therapeutix, Inc.

2021 - 2023

  • Board Chair

    2021 - 2023

GT
G1 Therapeutics, Inc.

2014 - 2020

  • CEO, Board Director

    2014 - 2020

YU
Yale University School of Medicine

1997 - 2017

  • Assistant Clinical Professor (adjunct)

    1999 - 2017

  • Associate Research Scientist

    1997 - 1999

TL
The Leukemia & Lymphoma Society

2012 - 2014

  • Chief Policy and Advocacy Officer

    2012 - 2014